Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTN-038: 90-Day Tenofovir Intravaginal Ring PK and Safety
NCT03670355Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Tenofovir (TFV) Intravaginal Ring (IVR) with Placebo IVR (2 arms). Primary endpoints: Tenofovir Levels in Plasma at Day 92, Tenofovir Levels in Cervicovaginal Fluid at Day 92 and 5 more. Started Jan 2019; status: completed.
02
Drugs
tenofovir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03670355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03670355.